Skip to Content
  • Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
  • Article
  • Open Access

9 May 2013

Poly-Ingredient Formulation Bresol® Ameliorates Experimental Chronic Obstructive Pulmonary Disease (COPD) in Rats

,
,
,
,
,
and
Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka, India
*
Author to whom correspondence should be addressed.

Abstract

In the present study, the protective effect of Bresol® – a polyherbal formulation – was evaluated in an experimental model of cigarette smoke (CS)-induced COPD in rats. Ten minutes daily exposure to CS for 7 weeks caused significant elevation of TNF-α (p<0.01) and total protein (p<0.01) in the bronchoalveolar lavage fluid (BALF) of positive untreated control animals, indicating ongoing inflammatory process in the lungs. Further, histopathological findings have confirmed the presence of pathological lesions in the trachea and lungs. Five weeks of post-treatment with Bresol® (250 and 500 mg/kg,p.o.) showed significant and dose-dependent anti-inflammatory effects against CS-induced lung abnormalities by maintaining the TNF-α and total protein levels within the normal range. Additionally, Bresol®-treated animals showed normal cyto-architecture of the trachea and lungs. In conclusion, Bresol® showed dose-dependent protection against CS-induced lung and tracheal injury in rats, which further indicates, Bresol® is a useful healing agent, may help to decelerate the progression of COPD, and reduce the exacerbations in patients.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.